Mydecine seeks to become a psilocybin supplier for new applications for psilocybin-therapy under Canada's SAP.
Mydecine seeks to become a psilocybin supplier for new applications for psilocybin-therapy under Canada's SAP.
The Mental Health Crisis spirals. Psychedelic medicine advances. In 2022, "crisis" meets "opportunity".
atai Life Sciences announces Investigational New Drug (IND) clearance from the FDA for PCN-101.
Wesana announces a pre-IND meeting with the FDA for SANA-013 in March, it's lead drug candidate for Traumatic Brain Injury.
Awakn announces strong results from its Phase II a/b clinical trial of a ketamine-assisted therapy for Alcohol Use Disorder (AUD).
Field Trip announces receiving its USPTO patent for FT-104, including composition of matter.
On January 5, 2022, Health Canada amendments to its Special Access Program has expanded access to psychedelic drug therapies. We explore the implications.
Mydecine announces the use of AI to accelerate identification of drug candidates for psychedelics research.
On January 4, 2022, amendments to Health Canada's Special Access Program took effect that explicitly include access to psychedelic medicine. We asked Numinus' Payton Nyquvest to connect the dots on the impact of these new rules.
MindMed announces successfully completing Phase I for 18-MC, with patients receiving dosages of up tp 325 mg.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now